Reslizumab - Teva Pharmaceuticals

Drug Profile

Reslizumab - Teva Pharmaceuticals

Alternative Names: Anti-interleukin-5-monoclonal antibody-Celltech/Schering-Plough; CDP-835; CEP-38072; CINQAERO; CINQAIR; Cinquil; CTx-55700; DCP-835; SCH 55700; TRFK-5

Latest Information Update: 03 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Celltech R&D; Schering-Plough
  • Developer Allergy and Asthma Clinical Research; Celltech R&D; Teva Pharmaceutical Industries
  • Class Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action Interleukin 5 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Oesophagitis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Asthma
  • Phase III Sinusitis
  • Phase II Churg-Strauss syndrome
  • No development reported Oesophagitis

Most Recent Events

  • 02 Mar 2018 Pooled efficacy data from two phase III trials in Asthma presented at the 2018 Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAI-2018)
  • 31 Jan 2018 Teva completes a phase III trial in Asthma (In adolescents, In the elderly, Treatment-experienced, In adults) in USA, Australia, Argentina, Belgium, Canada, Japan, Turkey, Romania, New Zealand, Poland, Russia, South Africa, Ukraine, Czech Republic, Hungary, Spain, France, Germany, Israel, Italy, South Korea, Mexico and Netherlands (SC) (NCT02452190)
  • 04 Dec 2017 Teva completes a phase III study in Asthma (In adolescents, In adults, In the elderly, Treatment-experienced) in USA, Australia, Czech Republic, Poland, Argentina, Belgium, France, Germany, Hugery, Israel, Italy, Mexico, South Korea, the Netherlands, Russia, Spain, Ukrain (NCT02501629)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top